Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06668792 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma

Study acronym: FLAMMINGO
StatusRecruiting
PhasePhase 2
SponsorBiocad
Started2024-12-26
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 4, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2025-02-03
Not Yet Recruiting→Recruiting Study Identification, Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-11→confirmed 2024-12-26
Study sitesdetails revised at 20 of 20 sites
Study titlerevised
An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients withWith Relapsed/Refractory Multiple Myeloma
2024-10-30
Original filing
Biocad
26 trials monitored
See all monitored trials
Multiple Myeloma
1,228 trials monitored
See 75 trials at risk
The aim of the study is to assess the efficacy and safety of BCD-248 as a therapy for relapsing and/or refractory multiple myeloma.
Trial Details
NCT Number NCT06668792
Lead Sponsor Biocad
Conditions Relapsed/Refractory Multiple Myeloma
Enrollment 100 participants
Start Date 2024-12-26
Primary Completion 2026-02 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2025-02-04